Cryo-Cell International, Inc. (CCEL)

US — Healthcare Sector
Peers: NHC  INNV  PNTG  EHC  AIH  AIRS  AVAH  TOI  BKD  SGRY  SEM  ENSG  MD  PIII  SNDA  ACHC  DCGO  CCM 

Automate Your Wheel Strategy on CCEL

With Tiblio's Option Bot, you can configure your own wheel strategy including CCEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CCEL
  • Rev/Share 3.9721
  • Book/Share -1.8134
  • PB -2.8069
  • Debt/Equity -0.9457
  • CurrentRatio 0.5759
  • ROIC 0.0039

 

  • MktCap 41138194.0
  • FreeCF/Share 0.509
  • PFCF 10.0
  • PE 319.6217
  • Debt/Assets 0.2153
  • DivYield 0.0786
  • ROE -0.0107

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2024
CCEL
Published: February 28, 2025 by: Business Wire
Sentiment: Neutral

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2024. Financial Results Revenue Consolidated revenues for fiscal 2024 were $32.0 million compared to $31.3 million for fiscal 2023. The revenues for fiscal 2024 consisted of $31.6 million in processing and storage fee revenue, $68,000 in product revenue.

Read More
image for news Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2024

About Cryo-Cell International, Inc. (CCEL)

  • IPO Date 1994-04-04
  • Website https://www.cryo-cell.com
  • Industry Medical - Care Facilities
  • CEO Mr. David I. Portnoy
  • Employees 82
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.